11018-89-6C[C@@H]1O[C@@H](O[C@H]2C[C@@H](O)[C@]3(CO)C4C(CC[C@]3(O)C2)[C@@]2(O)CC[C@H](C3=CC(=O)OC3)[C@@]2(C)C[C@H]4O)[C@H](O)[C@H](O)[C@H]1OLPMXVESGRSUGHW-XPXORLBYSA-NPharmakon1600-01500676 has been reported in Digitalis purpurea with data available.
11018-89-6Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
DescriptionOuabain (11018-89-6) is a selective inhibitor of Na+ K+-ATPase isolated from Strophanthus gratus.1 Endogenous ouabain is found in human circulation.2 Displays cardiotonic and diuretic activity. May be used to induce hypertensive rat model.3Cell permeable and active in vivo.
UsesA cardiac glycoside that inhibits Na(+)/K(+) ATPase. It regulates transcription of MDR (increase, Pgp) and MRP (increase MRP1 and decrease CFTR, cyctic fibrosis transport receptor or cAMP-activated Cl- channel) genes, also alters localization of MRP1.
Usesantiarrhythmic, cardiotonic, hypertensive, Na/K ATPase inhibitor
Uses5HT2 receptor antagonist
UsesOuabain octahydrate, is used as a tool to induce in vivo excitotoxicity. Ouabain, as well as other endogenous digitalis-like compounds, can down-regulate the expression of 14-3-3 proteins in rat lens.
General DescriptionPharmaceutical secondary standards for application in quality control provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards
No reaction records under the current filter.
Loading…